The GoldspireTM Platform: A Personalized Biologic-Device Combination Approach to Generate Innate & Adaptive Anti-Tumor Immunity via Immunogenic Cell Death Mechanisms
Time: 3:30 pm
day: Conference Day Two
Details:
- Positive results seen in Phase 1b GBM trial
- Phase 2b study is recruiting
- Immunogenic cell death-associated markers in combination with evidence of anti-tumor immune responses in murine models and patient samples supports the underlying mechanism of action of GoldspireTM
